Author name: lara.james

At Lhasa we know that there are many challenges involved in carrying out risk assessments for drug substances and drug products, to ultimately ensure a safe and effective product for patients. Forced degradation studies are essential in pharmaceutical development to assess drug stability and ensure product quality and safety. These studies help identify degradation pathways,

Identification and control of impurities in active pharmaceutical ingredients (APIs) and pharmaceutical drug products is critical in drug development. Mirabilis is our innovative solution designed to address this challenge. In this post, we’ll answer ten frequently asked questions about Mirabilis.   What is Mirabilis? Mirabilis is an in silico tool developed by Lhasa Limited that

We are delighted to share our important new open access article: In silico prediction of pharmaceutical degradation pathways: A benchmarking study using the software program Zeneth. The paper, recently published in Organic Process Research & Development (OPRD) is authored by Lhasa Principal Scientist Rachel Hemingway, alongside industry expert co-authors from AstraZeneca, GSK, Pfizer, BMS, Amgen

Revised guidance released by the European Medicines Agency (EMA) on 7th July sparked excitement within the scientific community. By unveiling a new system to classify nitrosamines, EMA demonstrates that regulators are supporting industry in solving the complex problem of nitrosamine impurity assessment. The new approach will benefit industry, regulators and ultimately patients. What exactly are the